NCT07075185View on ClinicalTrials.gov

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 16, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

May 31, 2042

Conditions
Multiple Myeloma in RelapseMyeloma MultipleMultiple Myeloma ProgressionNeoplasms by Histologic TypeNeoplasmHemostatic DisordersVascular DisorderParaproteinemiasBlood Protein DisordersHematologic Disease and DisordersLymphoproliferative DisordersImmunoproliferative DisordersImmune System DiseaseGene Therapy
Interventions
DRUG

KLN-1010

Given at specified dose one time

Trial Locations (3)

2050

RECRUITING

The Royal Prince Alfred, Camperdown

3000

RECRUITING

Peter MacCallum Cancer Centre, Melbourne

3004

RECRUITING

The Alfred Paula Fox Melanoma and Cancer Centre, Melbourne

Sponsors
All Listed Sponsors
lead

Kelonia Therapeutics, Inc.

INDUSTRY